Keywords
Last Name

Jussi J. Saukkonen, MD

TitleAssociate Professor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionPulmonary, Allergy, Sleep & Critical Care Medicine
Address72 E. Concord St Housman (R)
Boston MA 02118
Phone(617) 638-6120
Other Positions
InstitutionVA Boston Healthcare System

TitleActive Staff Privileges
InstitutionBoston Medical Center
DepartmentMedicine
DivisionPulmonary, Allergy, Sleep & Critical Care Medicine

 Research Expertise & Professional Interests
Special Interests:

-Biomarker development for tuberculosis diagnosis and response to therapy
-mechanisms of innate (macrophage) immunity in tuberculosis.
-modulation of the macrophage response to TB by chemokines,
-effect of microbial pathogen recognition receptors on chemokine expression.

Clinical Research interests:
-Biomarker development for tuberculosis diagnosis and response to therapy
-latent tuberculosis treatment trials
-tuberculosis disease treatment trials
-multi-drug resistant tuberculosis
-extensively drug-resistant tuberculosis
-hepatotoxicity of anti-tuberculosis medications/drug safety
-inhalation technology, inhaled xenon for organ protection, “smart” ventilators


Tuberculosis Research and Initiatives:

Our TB Clinical Research Group at Boston University School of Medicine’s Pulmonary Center is engaged in multi-center consortium studies, investigator-initiated local research studies, and educational efforts locally, regionally, nationally, and internationally. Our site has been active within the Centers for Disease Control’s Tuberculosis Trials Consortium (TBTC), the largest international consortium of its type, enrolling patients in both latent and active TB treatment trials and in pharmacokinetic studies. I serve on the Core Sciences Group, the major scientific oversight committee for this consortium, the Multi-Drug Resistant (MDR) Tuberculosis Working Group, and the Biomarker Working Group. Through work on the MDR-TB WG, I am honored to be Co-PI with a great research team on TBTC USPHS Study 30 which is Linezolid for Multi-drug resistance In Tuberculosis (LiMiT) Study, USPHS Study 30. This is a randomized, controlled trial of linezolid versus placebo with both arms receiving optimized background therapy for drug-resistant TB. Within this study we will conduct a biomarker sub-study to assess serum protein s’, clinical and other variables’ ability to predict response to TB therapy. Within the TBTC Biomarker Group, we are expanding the ability of TBTC to conduct biomarker studies in all TBTC trials, an effort which has already started with TBTC Studies 29 and 30. TBTC’s biomarker effort will also include measures of hepatotoxicity. I am chairing the TBTC Hepatotoxicity Working Group, which will standardize data collection and develop initiatives for biomarker collaborations in hepatotoxicity.

Other activities from our TB Clinical Research Group include helping found and participate in RESIST-TB, an international consortium formed to conduct trial of drug resistant TB. I serve on the Scientific Advisory Committee and the Treatment Shortening Committees of RESIST-TB.

Our group concluded a study comparing hepatotoxicity and treatment completion with isoniazid for 6 months versus rifampin and pyrazinamide for two months. This study demonstrated substantially more hepatotoxicity and no improvement in treatment completion with the two month rifampin and pyrazinamide regimen, which is now no longer recommended. An outgrowth of that work was a multi-disciplinary national effort to review epidemiology, pathogenesis, and risk factors for “Hepatotoxicity of Anti-Tuberculosis Treatment”. The resulting document was adopted by the American Thoracic Society as an official statement.

We have also completed a study identifying predictors of failure to complete treatment for latent tuberculosis infection at the first clinic visit, and we are working on patient acceptance of interferon-gamma release assay results versus traditional tuberculin skin tests.

Inhalation Technology:

As Associate Program Leader for the Inhalation Technology Program at Center for Integration of Medicine and Innovative Technology (CIMIT), I am working to develop new therapies for respiratory and other diseases. This new program brings together multi-disciplinary efforts to tackle major clinic needs involving the respiratory tract, either as a site of disease in need of treatment or as a route to systemic administration of therapy for disease elsewhere in the body. A novel project to launch soon will be inhaled xenon for neuroprotection.

Clinical Interests:

My clinical interests in the outpatient arena include tuberculosis, asthma, allergy and immunology, pulmonary complications of HIV infection, COPD, interstitial fibrosis, and general pulmonary medicine.

 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Moro RN, Sterling TR, Saukkonen J, Vernon A, Horsburgh CR, Chaisson RE, Hamilton CD, Villarino ME, Goldberg S. Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. Int J Tuberc Lung Dis. 2017 Jan 13. PMID: 28087928.
    View in: PubMed
  2. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 Oct 1; 63(7):853-67. PMID: 27621353.
    View in: PubMed
  3. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 Oct 1; 63(7):e147-95. PMID: 27516382.
    View in: PubMed
  4. Moro RN, Borisov AS, Saukkonen J, Khan A, Sterling TR, Villarino ME, Scott NA, Shang N, Kerrigan A, Goldberg SV. Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. Clin Infect Dis. 2016 Jun 1; 62(11):1390-400. PMID: 26951571.
    View in: PubMed
  5. Jayakumar A, Vittinghoff E, Segal MR, MacKenzie WR, Johnson JL, Gitta P, Saukkonen J, Anderson J, Weiner M, Engle M, Yoon C, Kato-Maeda M, Nahid P. Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis. Tuberculosis (Edinb). 2015 Jul; 95(4):415-20. PMID: 26022314.
    View in: PubMed
  6. Kane M, Korn B, Saukkonen J, McDonald C, Walsh C, Waters R, McLaughlin AM, Keane J. Barriers to accepting and completing latent tuberculosis infection treatment. Ir Med J. 2013 Jul-Aug; 106(7):200-4. PMID: 24218745.
    View in: PubMed
  7. Hales CM, Heilig CM, Chaisson R, Leung CC, Chang KC, Goldberg SV, Gordin F, Johnson JL, Muzanyi G, Saukkonen J, Vernon A, Villarino ME, Burman WJ. The association between symptoms and microbiologically defined response to tuberculosis treatment. Ann Am Thorac Soc. 2013 Feb; 10(1):18-25. PMID: 23509328.
    View in: PubMed
  8. Padayatchi N, Mac Kenzie WR, Hirsch-Moverman Y, Feng PJ, Villarino E, Saukkonen J, Heilig CM, Weiner M, El-Sadr WM. Lessons from a randomised clinical trial for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012 Dec; 16(12):1582-7. PMID: 23131255.
    View in: PubMed
  9. Goswami ND, Gadkowski LB, Piedrahita C, Bissette D, Ahearn MA, Blain ML, Østbye T, Saukkonen J, Stout JE. Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health. 2012; 12:468. PMID: 22720842.
    View in: PubMed
  10. Lamunu D, Chapman KN, Nsubuga P, Muzanyi G, Mulumba Y, Mugerwa MA, Goldberg S, Bozeman L, Engle M, Saukkonen J, Mastranunzio S, Mayanja-Kizza H, Johnson JL. Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment. Int J Tuberc Lung Dis. 2012 Apr; 16(4):480-5. PMID: 22640513.
    View in: PubMed
  11. Saukkonen JJ, Powell K, Jereb JA. Monitoring for tuberculosis drug hepatotoxicity: moving from opinion to evidence. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):598-9. PMID: 22422902.
    View in: PubMed
  12. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med. 2011 Oct 15; 184(8):972-9. PMID: 21737585.
    View in: PubMed
  13. O'Donnell MR, Coe A, Bliss C, Lee D, Tumilty S, Skolnik PR, Horsburgh CR, Cotton D, Saukkonen J. Acceptance of interferon-gamma release assay by a high-risk urban cohort. Int J Tuberc Lung Dis. 2011 Oct; 15(10):1334-9. PMID: 22283891.
    View in: PubMed
  14. Heilig CM, Chia D, El-Sadr WM, Hirsch-Moverman Y, Kenzie WR, Saukkonen J, Villarino ME, Padayatchi N. Justifying research risks in a clinical trial for treatment of multidrug-resistant tuberculosis. IRB. 2011 Jul-Aug; 33(4):10-7. PMID: 21932482.
    View in: PubMed
  15. Saukkonen J. Challenges in reintroducing tuberculosis medications after hepatotoxicity. Clin Infect Dis. 2010 Mar 15; 50(6):840-2. PMID: 20156056.
    View in: PubMed
  16. Patel NR, Zhu J, Tachado SD, Zhang J, Wan Z, Saukkonen J, Koziel H. HIV impairs TNF-alpha mediated macrophage apoptotic response to Mycobacterium tuberculosis. J Immunol. 2007 Nov 15; 179(10):6973-80. PMID: 17982088.
    View in: PubMed
  17. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006 Oct 15; 174(8):935-52. PMID: 17021358.
    View in: PubMed
  18. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med. 2006 Sep 15; 174(6):717-21. PMID: 16809632.
    View in: PubMed
  19. Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh CR. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect. 2007 Mar; 54(3):262-6. PMID: 16772095.
    View in: PubMed
  20. Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med. 2004 Dec 15; 170(12):1360-6. PMID: 15477492.
    View in: PubMed
  21. Saukkonen J. Rifampin and pyrazinamide for latent tuberculosis infection: clinical trials and general practice. Clin Infect Dis. 2004 Aug 15; 39(4):566-8. PMID: 15356823.
    View in: PubMed
  22. Wilson KC, Saukkonen JJ. Acute respiratory failure from abused substances. J Intensive Care Med. 2004 Jul-Aug; 19(4):183-93. PMID: 15296619.
    View in: PubMed
  23. Jasmer RM, Snyder DC, Saukkonen JJ, Hopewell PC, Bernardo J, King MD, Kawamura LM, Daley CL. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. Clin Infect Dis. 2004 Feb 1; 38(3):363-9. PMID: 14727206.
    View in: PubMed
  24. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002 Oct 15; 137(8):640-7. PMID: 12379063.
    View in: PubMed
  25. Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J, Kornfeld H. Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect Immun. 2002 Apr; 70(4):1684-93. PMID: 11895930.
    View in: PubMed
  26. Jones BW, Heldwein KA, Means TK, Saukkonen JJ, Fenton MJ. Differential roles of Toll-like receptors in the elicitation of proinflammatory responses by macrophages. Ann Rheum Dis. 2001 Nov; 60 Suppl 3:iii6-12. PMID: 11890657.
    View in: PubMed
  27. Saukkonen JJ, Tantri A, Berman J. Costimulation of CD28- T cells through CD3 and beta1-integrins induces a limited Th1 cytokine response. Scand J Immunol. 1999 Aug; 50(2):145-9. PMID: 10447918.
    View in: PubMed
  28. Mashikian MV, Tarpy RE, Saukkonen JJ, Lim KG, Fine GD, Cruikshank WW, Center DM. Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients. J Allergy Clin Immunol. 1998 Jun; 101(6 Pt 1):786-92. PMID: 9648706.
    View in: PubMed
  29. Saukkonen JJ, Furfaro S, Mahoney KM, Strieter RM, Burdick M, Wright EA, Kornfeld H, Berman JS. In vitro transendothelial migration of blood T lymphocytes from HIV-infected individuals. AIDS. 1997 Nov; 11(13):1595-601. PMID: 9365764.
    View in: PubMed
  30. Hendra KP, Saukkonen JJ. Erosion of the right mainstem bronchus by an esophageal stent. Chest. 1996 Sep; 110(3):857-8. PMID: 8797444.
    View in: PubMed
  31. Berman JS, Mahoney K, Saukkonen JJ, Masuyama J. Migration of distinct subsets of CD8+ blood T cells through endothelial cell monolayers in vitro. J Leukoc Biol. 1995 Sep; 58(3):317-24. PMID: 7665987.
    View in: PubMed
  32. Saukkonen JJ, Kornfeld H, Berman JS. Expansion of a CD8+CD28- cell population in the blood and lung of HIV-positive patients. J Acquir Immune Defic Syndr. 1993 Nov; 6(11):1194-204. PMID: 8229654.
    View in: PubMed
  33. Dougherty TJ, Saukkonen JJ. Membrane permeability changes associated with DNA gyrase inhibitors in Escherichia coli. Antimicrob Agents Chemother. 1985 Aug; 28(2):200-6. PMID: 3010837.
    View in: PubMed
  34. Schoemaker JM, Clark JM, Saukkonen JJ. Characterization of polysaccharide accumulation in a cell division defective mutant of Escherichia coli 15T-. J Gen Microbiol. 1981 Apr; 123(2):323-33. PMID: 7033459.
    View in: PubMed
  35. Schoemaker JM, Schoemaker PJ, Saukkonen JJ. Polysaccharide accumulation in the cell division defective mutant, Escherichia coli 15T-R1. Microbios. 1980; 29(117-118):149-59. PMID: 7026982.
    View in: PubMed
  36. Simenhoff ML, Saukkonen JJ, Burke JF, Schaedler RW, Vogel WH, Bovee K, Lasker N. Importance of aliphatic amines in uremia. Kidney Int Suppl. 1978 Jun; (8):S16-9. PMID: 357815.
    View in: PubMed
  37. Simenhoff ML, Saukkonen JJ, Burke JF, Wesson LG, Schaedler RW, Gordon SJ. Bacterial populations of the small intestine in uremia. Nephron. 1978; 22(1-3):63-8. PMID: 745639.
    View in: PubMed
  38. Simenhoff ML, Burke JF, Saukkonen JJ, Ordinario AT, Doty R. Biochemical profile or uremic breath. N Engl J Med. 1977 Jul 21; 297(3):132-5. PMID: 865584.
    View in: PubMed
  39. Ryhänen P, Saarela E, Saukkonen J, Hollmén A. Circulatory responses to laryngoscopy and endotracheal intubation in patients with and without cardiovascular disease. Effect of prophylactic practolol. Ann Chir Gynaecol. 1977; 66(6):294-8. PMID: 603221.
    View in: PubMed
  40. Simenhoff ML, Saukkonen JJ, Burke JF, Wesson LG, Schaedler RW. Amine metabolism and the small bowel in uraemia. Lancet. 1976 Oct 16; 2(7990):818-21. PMID: 61496.
    View in: PubMed
  41. Simenhoff M, Saukkonen J, Schaedler R, Gordon S, Burke J. Proceedings: Amine metabolism and the small intestinal flora in uraemia. Clin Sci Mol Med. 1974 Apr; 46(4):23P. PMID: 4829857.
    View in: PubMed
  42. Hollmén A, Saukkonen J. The effects of postoperative epidural analgesia versus centrally acting opiate on physiological shunt after upper abdominal operation. Acta Anaesthesiol Scand. 1972; 16(3):147-54. PMID: 4644712.
    View in: PubMed
  43. Hollmén A, Saukkonen J. Effect of epidural or general anaesthesia on the arterial acid-base balance, oxygenation and venous admixture in prostatectomy patients. Ann Clin Res. 1971 Jun; 3(3):168-75. PMID: 5558130.
    View in: PubMed
  44. Hollmén A, Karvonen S, Saukkonen J, Valanne J. Treatment of experimental haemorrhagic shock in dogs. Ann Chir Gynaecol Fenn. 1970; 59(3):119-26. PMID: 5507359.
    View in: PubMed
  45. Hollmén A, Saukkonen J. [Postoperative elimination of pain following upper abdominal surgery. Anesthetics, intercostal block and epidural anesthesia and their effect on respiration]. Anaesthesist. 1969 Sep; 18(9):298-303. PMID: 5380963.
    View in: PubMed
  46. Hollmén A, Saukkonen J. Postoperative serum glutamic-oxalacetic transaminase and glutamic-pyruvic transaminase changes in biliary patients. Acta Anaesthesiol Scand. 1967; 11(4):393-400. PMID: 5597538.
    View in: PubMed
  47. Lahti A, Saukkonen JJ. Immunodiffusion analysis of subcellular fractions of Escherichia coli. Ann Med Exp Biol Fenn. 1966; 44(2):216-20. PMID: 4961009.
    View in: PubMed
  48. Takala JK, Voutilainen A, Saukkonen J. [Spontaneous regression of cancer]. Duodecim. 1966; 82(8):383-7. PMID: 5931626.
    View in: PubMed
  49. Saukkonen JJ. [Nucleic acids--the structural basis of the gene]. Duodecim. 1965; 81(11):632-40. PMID: 5840450.
    View in: PubMed
  50. Cantell K, Valle M, Schakir R, Saukkonen JJ, Uroma E. Observations on production, assay and purification of chick embryo interferon. Ann Med Exp Biol Fenn. 1965; 43(3):125-31. PMID: 4286218.
    View in: PubMed
  51. GREF CG, SAUKKONEN JJ. INEXPENSIVE AND PRACTICAL EQUIPMENT FOR THIN-LAYER CHROMATOGRAPHY. Anal Biochem. 1964 May; 8:132-4. PMID: 14167267.
    View in: PubMed
  52. PIRILA V, SAUKKONEN J, SANTAOJA IM. HYPERSENSITIVITY TO BACITRACIN. THE INFLUENCE OF DEGRADATION UPON ITS ECZEMATOGENIC EFFECT. J Invest Dermatol. 1964 Jan; 42:137-40. PMID: 14110902.
    View in: PubMed
  53. Saukkonen JJ. Chromatography of free nucleotides. Chromatogr Rev. 1964; 6:53-90. PMID: 5337014.
    View in: PubMed
  54. SAUKKONEN JJ, LAHTI A, VAINIO T. Serological crossreactivity between a ribitol teichoic acid and a component of Escherichia coli. Biochem Biophys Res Commun. 1963 Jul 18; 12:126-31. PMID: 13986813.
    View in: PubMed
  55. LAHTI A, SAUKKONEN J, VAINIO T, ALLAS Y. DOUBLE DIFFUSION PRECIPITATION AND IMMUNOELECTROPHORESIS OF E. COLI B ANTIGENS. Acta Pathol Microbiol Scand. 1963; 58:517-20. PMID: 14048674.
    View in: PubMed
  56. SAUKKONEN JJ, VIRKOLA P. Acid-soluble nucleotides of Staphylococcus aureus. II. Methods of preparation. Ann Med Exp Biol Fenn. 1963; 41:220-7. PMID: 13986812.
    View in: PubMed
  57. SAUKKONEN JJ, VIRKOLA P. Acid-soluble nucleotides of Staphylococcus aureus. III. Studies on the mode of action of penicillin. Ann Med Exp Biol Fenn. 1963; 41:228-36. PMID: 13986811.
    View in: PubMed
  58. LAHTI A, SAUKKONEN J, VAINIO T, ALLAS Y. STUDIES ON COLIPHAGE T2R SPECIFIC ANTIGENS BY MEANS OF DOUBLE DIFFUSION PRECIPITATION AND IMMUNOELECTROPHORESIS. Acta Pathol Microbiol Scand. 1963; 59:124-8. PMID: 14058777.
    View in: PubMed
  59. SAUKKONEN JJ. Occurrence of new nucleotides in penicillin-inhibited Staphylococcus aureus. Acta Pathol Microbiol Scand Suppl. 1962; Suppl 154:322. PMID: 14497517.
    View in: PubMed
  60. SAUKKONEN JJ. [Molecular biology, the chemical basis of genetics]. Duodecim. 1962; 78:1057-62. PMID: 13986810.
    View in: PubMed
  61. SAUKKONEN JJ. [Nobel Prize winners in medicine and physiology 1962]. Duodecim. 1962; 78:973-6. PMID: 13986809.
    View in: PubMed
  62. SAUKKONEN JJ. Acid-soluble nucleotides of Staphylococcus aureus: massive accumulation of a derivative of cytidine diphosphate in the presence of penicillin. Nature. 1961 Dec 2; 192:816-7. PMID: 14497516.
    View in: PubMed
  63. SAUKKONEN JJ, CANTELL K. Concentration of blood group anti-sera. A simple technique. Ann Med Exp Biol Fenn. 1961; 39:218-24. PMID: 14037637.
    View in: PubMed
  64. SAUKKONEN JJ, GOODMAN F, CHARGAFF E. Patterns of cellular controls operating in bacteriophage reproduction. II. Effect of 5-fluorouracil on metabolic events in bacteria infected with coliphage T2r. Biochim Biophys Acta. 1960 Nov 18; 44:469-77. PMID: 13746781.
    View in: PubMed
  65. GOODMAN F, SAUKKONEN JJ, CHARGAFF E. Patterns of cellular controls operating in bacteriophage reproduction. I. Effect of 5-fluorouracil in the multiplication of several coliphages. Biochim Biophys Acta. 1960 Nov 18; 44:458-68. PMID: 13707028.
    View in: PubMed
  66. HOROWITZ J, SAUKKONEN JJ, CHARGAFF E. Effects of fluoropyrimidines on the synthesis of bacterial proteins and nucleic acids. J Biol Chem. 1960 Nov; 235:3266-72. PMID: 13715937.
    View in: PubMed
  67. HOROWITZ J, SAUKKONEN JJ, CHARGAFF E. Effect of 5-fluorouracil on a uracil-requiring mutant of Escherichia coli. Biochim Biophys Acta. 1958 Jul; 29(1):222-3. PMID: 13560476.
    View in: PubMed
  68. SAUKKONEN JJ. [Incidence of free nucleotides in dormant and growing tissue]. Ann Med Exp Biol Fenn. 1956; 34(Suppl 3):1-78. PMID: 13340350.
    View in: PubMed
Jussi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department